METOPROLOL SUCCINATE ER tablet, extended release

Riik: Ameerika Ühendriigid

keel: inglise

Allikas: NLM (National Library of Medicine)

Toimeaine:

METOPROLOL SUCCINATE (UNII: TH25PD4CCB) (METOPROLOL - UNII:GEB06NHM23)

Saadav alates:

Northwind Pharmaceuticals

INN (Rahvusvaheline Nimetus):

METOPROLOL SUCCINATE

Koostis:

METOPROLOL TARTRATE 100 mg

Manustamisviis:

ORAL

Retsepti tüüp:

PRESCRIPTION DRUG

Näidustused:

1.1 Hypertension Metoprolol succinate extended-release tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety

Toote kokkuvõte:

Metoprolol succinate extended-release tablets USP, 100 mg are white to off-white, round shaped, film-coated tablets, debossed with “M” and “3” separated by breakline on one side and plain on other side. They are supplied in bottles of 30, 60, 100, 500 and unit dose packages of 100 (10x10). Bottles of 30 NDC 55111-468-30 Bottles of 60 NDC 55111-468-60 Bottles of 100 NDC 55111-468-01 Bottles of 500 NDC 55111-468-05 Unit dose packages of 100 (10x10) NDC 55111-468-78 Metoprolol succinate extended-release tablets USP, 200 mg are white to off-white, oval shaped film-coated tablets, debossed with “M” and “4” separated by breakline on one side and plain on other side. They are supplied in bottles of 30, 60, 100, 500 and unit dose packages of 100 (10x10). Bottles of 30 NDC 55111-469-30 Bottles of 60 NDC 55111-469-60 Bottles of 100 NDC 55111-469-01 Bottles of 500 NDC 55111-469-05 Unit dose packages of 100 (10x10) NDC 55111-469-78 Store at 20°-25°C (68°-77°F); [See USP Controlled Room Temperature.] Please review the manufacturer's complete drug information available from the FDA at www.fda.gov Permanent Link: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=71c1d33e-be6f-6d59-b715-45075445891a

Volitamisolek:

Abbreviated New Drug Application

Toote omadused

METOPROLOL SUCCINATE ER- METOPROLOL SUCCINATE ER TABLET, EXTENDED
RELEASE
NORTHWIND PHARMACEUTICALS
----------
METOPROLOL SUCCINATE ER 100MG
INDICATIONS AND USAGE
1.1 Hypertension
Metoprolol succinate extended-release tablets are indicated for the
treatment of hypertension, to lower
blood pressure. Lowering blood pressure lowers the risk of fatal and
non-fatal cardiovascular events,
primarily strokes and myocardial infarctions. These benefits have been
seen in controlled trials of
antihypertensive drugs from a wide variety of pharmacologic classes
including metoprolol.
Control of high blood pressure should be part of comprehensive
cardiovascular risk management,
including, as appropriate, lipid control, diabetes management,
antithrombotic therapy, smoking cessation,
exercise, and limited sodium intake. Many patients will require more
than 1 drug to achieve blood
pressure goals. For specific advice on goals and management, see
published guidelines, such as those
of the National High Blood Pressure Education Program’s Joint
National Committee on Prevention,
Detection, Evaluation, and Treatment of High Blood Pressure (JNC).
Numerous antihypertensive drugs, from a variety of pharmacologic
classes and with different
mechanisms of action, have been shown in randomized controlled trials
to reduce cardiovascular
morbidity and mortality, and it can be concluded that it is blood
pressure reduction, and not some other
pharmacologic property of the drugs, that is largely responsible for
those benefits. The largest and
most consistent cardiovascular outcome benefit has been a reduction in
the risk of stroke, but reductions
in myocardial infarction and cardiovascular mortality also have been
seen regularly.
Elevated systolic or diastolic pressure causes increased
cardiovascular risk, and the absolute risk
increase per mmHg is greater at higher blood pressures, so that even
modest reductions of severe
hypertension can provide substantial benefit. Relative risk reduction
from blood pressure reduction is
similar across populati